Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | BRD2 | P25440 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2826636 | 0.87 | CA12 (0.47) | BRD4BRD2CREBBPCA12CA1 | |
| SCHEMBL7875608 | 0.87 | CA12 (0.47) | BRD4BRD2CREBBPCA12CA1 | |
| SCHEMBL22868140 | 0.87 | L3MBTL1 (0.48) | BRD4BRD2CREBBPCA12CA1 | |
| SCHEMBL16397245 | 0.86 | NOTUM (0.53) | BRD4BRD2CREBBPCA12CA1 | |
| SCHEMBL4757744 | 0.86 | MEN1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29173958 | 0.86 | PARP10 (0.43) | BRD4BRD2CREBBPCA12CA1 | |
| SCHEMBL31135164 | 0.86 | MEN1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2822392 | 0.86 | CA12 (0.46) | BRD4BRD2CREBBPCA12CA1 | |
| SCHEMBL2712707 | 0.85 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10180584 | 0.85 | CA12 (0.64) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024255762-A1 | CBL-B INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2024-12-19 | — | — | WO | disclosed |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| EP-4301752-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| CN-117295736-A | Benzo [ C ] [2,6] naphthyridine derivatives, compositions thereof and therapeutic uses thereof | 剑桥实业有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| WO-2022185041-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-09-09 | — | — | WO | disclosed |
| WO-2017006295-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-12 | — | — | WO | disclosed |
| EP-2427465-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| WO-2010129729-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129729-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010069504-A1 | (3-OXO)PYRIDIN-4-YLUREA DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL, S.A. (ES) | 2010-06-24 | — | — | WO | disclosed |
| EP-2196465-A1 | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | BRD4 95/4885BRD2 77/4885CREBBP 230/4885 |
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | SSTR5, SSTR2, GPR119 | BRD4 2507/4885BRD2 1733/4885CREBBP 1807/4885 |
| US-11866436-B2 | Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof | ABCB11, CEL, NDC1 | BRD4 203/4885BRD2 172/4885CREBBP 1093/4885 |
| US-20240287060-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | BRD4 95/4885BRD2 77/4885CREBBP 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.